Immatics (IMTX) Cash from Financing Activities (2019 - 2025)
Immatics' (IMTX) quarterly Cash from Financing Activities came in at $115.9 million in Q4 2025, down 25.91% year-on-year from $156.4 million in Q4 2024, and up 13604.66% quarter-over-quarter from -$858086.4 in Q3 2025.
Immatics (IMTX) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Immatics has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $115.9 million for Q4 2025.
- Cash from Financing Activities for Q4 2025 came in at $115.9 million, down 25.91% year-over-year; the trailing twelve-month figure through Dec 2025 was $113.4 million (down 67.09% YoY), and the FY2025 annual result was $110.0 million, down 67.8% from the prior year.
- Cash from Financing Activities came in at $115.9 million for Q4 2025 at Immatics, up from -$858086.4 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $189.7 million in Q1 2024 to a low of -$1.0 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is -$639942.7 (2021), against an average of $33.7 million.
- Across the five-year window, Cash from Financing Activities slumped 482.48% in 2021 and jumped 20511.49% in 2024, its largest moves.
- Immatics' Cash from Financing Activities stood at -$670367.0 in 2021, then surged by 16154.62% to $107.6 million in 2022, then plunged by 100.97% to -$1.0 million in 2023, then jumped by 15054.62% to $156.4 million in 2024, then retreated by 25.91% to $115.9 million in 2025.
- The last three Cash from Financing Activities figures came in at $115.9 million (Q4 2025), -$858086.4 (Q3 2025), and -$822934.7 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | 115.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 115.88 Mn |
| Dec 31, 2025 | 115.88 Mn |
| Sep 30, 2025 | -858,086.44 |
| Sep 30, 2025 | -858,086.44 |
| Jun 30, 2025 | -822,934.69 |
| Jun 30, 2025 | -822,934.69 |
| Mar 31, 2025 | -775,238.83 |
| Mar 31, 2025 | -775,238.83 |
| Dec 31, 2024 | 156.40 Mn |
| Dec 31, 2024 | 156.40 Mn |
| Sep 30, 2024 | -826,959.29 |
| Sep 30, 2024 | -826,959.29 |
| Jun 30, 2024 | -609,518.37 |
| Jun 30, 2024 | -609,518.37 |
| Mar 31, 2024 | 189.73 Mn |
| Mar 31, 2024 | 189.73 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Sep 30, 2023 | 54.32 Mn |
| Sep 30, 2023 | 54.32 Mn |